International Journal of Advanced and Integrated Medical Sciences

Register      Login

SEARCH WITHIN CONTENT

FIND ARTICLE

Volume / Issue

Online First

Archive
Volume  3 (2018)
Volume  2 (2017)
Volume  1 (2016)
Related articles

VOLUME 2 , ISSUE 4 ( 2017 ) > List of Articles

CASE REPORT

Excision of Oral Leukoplakia using 970 nm Diode Laser

Chaya M David, Malti Agrawal, Jyoti Thakur

Keywords : Ablation, Diode, Laser, Leukoplakia, Potentially malignant disorder

Citation Information : David CM, Agrawal M, Thakur J. Excision of Oral Leukoplakia using 970 nm Diode Laser. Int J Adv Integ Med Sci 2017; 2 (4):208-211.

DOI: 10.5005/jp-journals-10050-10109

License: CC BY-SA 4.0

Published Online: 01-06-2018

Copyright Statement:  Copyright © 2017; The Author(s).


Abstract

Oral leukoplakia (OL) is one of the most commonly seen potentially malignant disorders with varied clinical presentations. A wide variety of medical and surgical treatment modalities have been tried for its management with varying successes. Laser ablation of the lesion is considered as one of the treatment modalities. Conventional surgery may be followed by some side effects like scar formation, contraction, and contamination of surgical field. Using high-power laser has some advantages like less pain, swelling, bleeding, ability to decontaminate, thus preventing secondary infection. This article presents a case of leukoplakia in the right buccal mucosa, which was managed using a 6 W diode laser of 970 nm. The healing occurred uneventfully over a period of 1 month postoperatively with minimal patient discomfort. The case establishes the efficacy of diode laser in the management of OL. How to cite this article Gupta P, Thakur J, David CM. Excision of Oral Leukoplakia using 970 nm Diode Laser. Int J Adv Integ Med Sci 2017;2(4):208-211.

PDF Share
  1. Barnes L, Eveson JW, Reichart PA, Sidransky D. World Health Organization classification of tumours. Pathology & genetics. Head and neck tumours. Lyon: World Health Organization International Agency for Research on Cancer, IACR Press; 2005.
  2. Warnakulasuriya S, Johnson NW, van der Waal I. Nomenclature and classification of potentially malignant disorders of the oral mucosa. J Oral Pathol Med 2007 Nov;36(10):575-580.
  3. Brouns E, Baart JA, Bloemena E, Karagozoglu H, van der Waal I. The relevance of uniform reporting in oral leukoplakia: definition, certainty factor and staging based on experience with 275 patients. Med Oral Patol Oral Cir Bucal 2013 Jan;18(1):e19-e26.
  4. Gupta PC, Mehta FS, Daftary DK, Pindborg JJ, Bhonsle RB, Jalnawalla PN, Sinor PN, Pitkar VK, Murti PR, Irani RR, et al. Incidence rates of oral cancer and natural history of oral precancerous lesions in a 10-year follow-up study of Indian villagers. Community Dent Oral Epidemiol 1980 Aug;8(6):287-333.
  5. Tobacco-related oral mucosal lesions and dental diseases. Available from: www.corecentre.co.in/Database/Docs/DocFiles/Tobacco_04_7.pdf (Accessed on 15 June 2017).
  6. Greenberg MS, Glick M, Ship JA. Burket's oral medicine. 11th ed. Ontario: BC Decker Inc; 2003. pp. 57-60.
  7. Baric JM, Alman JE, Feldman RS, Chauncey HH. Influence of cigarette, pipe and cigar smoking, removal partial dentures and age on oral leukoplakia. Oral Surg Oral Med Oral Pathol 1982 Oct;54(4):424-429.
  8. Vlad R, Panainte I, Stoica A, Monea M. The prevalence of oral leukoplakia: results from a Romanian Medical Center. Eur Sci J 2016 Sep;12(27):12-17.
  9. Sankaranarayanan R, Mathew B, Varghese C, Sudhakaran PR, Menon V, Jayadeep A, Nair MK, Mathews C, Mahalingam TR, Balaram P, et al. Chemoprevention of oral leukoplakia with vitamin A and beta carotene: an assessment. Oral Oncol 1997 Jul;33(4):231-236.
  10. Coluzzi DJ. Laers and soft tissue curettage: an update. Compend Contin Educ Dent 2002 Nov;23(11A):1104-1111.
  11. Moritz A, Gutknecht N, Doertbudak O, Goharkhay K, Schoop U, Schauer P, Sperr W. Bacterial reduction in periodontal pockets through irradiation with a laser diode. J Clin Laser Med Surg 1997 Feb;15(1):33-37.
  12. Tatu R, Shah K, Palan S, Brahmakshatriy H, Patel R. Laser excision of labial leukoplakia with diode laser: a case report. IJRRMS 2013 Oct-Dec;3(4):64-66.
  13. Kharadi UA, Onkar S, Birangane R, Chaudhari S, Kulkarni A, Chaudhari R. Treatment of oral leukoplakia with diode laser: a pilot study on Indian subjects. Asian Pac J Cancer Prev 2015;16(18):8383-8386.
  14. Praveen KNS, Veeraraghavan G, Reddy RS, Kotha P, Koneru J, Yelisetty K. Management of oral leukoplakia using diode laser: a pilot study. Br J Med Med Res 2015;10(7):1-6.
  15. Hong WK, Endicott J, Itri LM, Doos W, Batsakis JG, Bell R, Fofonoff S, Byers R, Atkinson EN, Vaughan C, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J Med 1986 Dec;315(24):1501-1505.
  16. Natekar M, Raghuveer HP, Rayapati DK, Shobha ES, Prashanth NT, Rangan V, Panicker AG. A comparative evaluation: Oral leukoplakia surgical management using diode laser, CO2 laser, and cryosurgery. J Clin Exp Dent 2017 Jun;9(6):e779-6784.
  17. Goharkhay K, Moritz A, Wilder-Smith P, Schoop U, Kluger W, Jakolitsch S, Sperr W. Effects on oral soft tissue produced by a diode laser in vitro. Lasers Surg Med 1999;25(5):401-406.
  18. Saleh HM, Saafan AM. Excision biopsy of tongue lesions by diode laser. Photomed Laser Surg 2007 Feb;25(1):45-49.
  19. Van Hillegersberg R. Fundamentals of laser surgery. Eur J Surg 1997 Jan;163(1):3-12.
  20. Tuffin JR, Carruth JA. The carbon dioxide surgical laser. Br Dent J 1980;149(9):255-258.
  21. Nordestgaard BG, Langsted A, Freiberg JJ. Nonfasting hyperlipidemia and cardiovascular disease. Curr Drug Targets 2009 Apr;10(4):54-61.
  22. Peters AL. Clinical relevance of non-HDL cholesterol in patients with diabetes. Clin Diabetes 2008 Jan;26(1):3-7.
  23. Vaughan N, James K, McDermott D, Griest S, Fausti S. A 5-year prospective study of diabetes and hearing loss in a veteran population. Otol Neurotol 2006 Jan;27(1):37-43.
  24. Tosi A, Misciali C, Piraccini B, Peluso AM, Bardazzi F. Drug-induced hair loss and hair growth. Incidence, management and avoidance. Drug Saf 1994 Apr;10(4):310-317.
  25. Bronner AK, Hood AF. Cutaneous complication of chemotherapeutic agents. J Am Acad Dermatol 1983 Nov;9(5):645-663.
  26. Hood AF. Cutaneous side effects of cancer chemotherapy. Med Clin North Am 1986 Jan;70(1):187-209.
  27. Boyle DM, Engelking C. Vesicant extravasation: myths and realities. Oncol Nurs Forum 1995 Jan-Feb;22(1):57-67.
  28. Malkinson, FD. Radiobiology of the skin. In: Freedberg IM, Eisen AZ, Wolff K, Austen KF, Goldsmith LA, Katz SI, Fitzpatrick TB, editors. Fitzpatrick's dermatology in general medicine. 5th edn. New York: McGraw-Hill; 1999. pp. 1514-1523.
  29. Goldschmidt H, Breneman JC, Bareneman DL. Ionizing radiation therapy in dermatology. J Am Acad Dermatol 1994 Feb;30(2 Pt 1):157-182.
  30. Narkiewicz K, van de Borne P, Montano N, Hering D, Kara T, Somers VK. Sympathetic neural outflow and chemoreflex sensitivity are related to spontaneous breathing rate in normal men. Hypertension 2006;47(1):51-55.
  31. Agte VV, Chiplonkar SA. Sudarshan kriya yoga for improving antioxidant status and reducing anxiety in adults. Altern Complement Ther 2008;14(2):96-100.
  32. Jacobs GD. Clinical applications of the relaxation response and mind-body interventions. J Altern Complement Med 2001;7(Suppl 1):S93-S101.
  33. Singh N, Telles S. Heart rate variability and state anxiety in hypertensives and diabetes after one week of yoga. J Indian Psychol 2009;27(1-2):13-20.
  34. Williams B, Poulter NR, Brown MJ, Davis M, McInnes GT, Potter JF, Sever PS, McG Thom S; British Hypertension Society. Guidelines for management of hypertension: report of the fourth working party of the British Hypertension Society, 2004—BHS IV. J Hum Hypertens 2004 Mar;18(3):139-185.
  35. Rabi DM, Daskalopoulou SS, Padwal RS, Khan NA, Grover SA, Hackam DG, Myers MG, McKay DW, Quinn RR, Hemmelgarn BR, et al. The 2011 Canadian Hypertension Education Program recommendations for the management of hypertension: blood pressure measurement, diagnosis, assessment of risk, and therapy. Can J Cardiol 2011 Jul-Aug;27(4):415-433.e1-2.
  36. Wahlgren NG, MacMahon DG, De Keyser JF, Indredavik B, Ryman T. Intravenous Nimodipine West European Stroke Trial (INWEST) of nimodipine in the treatment of acute ischaemic stroke. Cerebrovasc Dis 1994 May;4(3):204-10.
  37. Kaste M, Fogelholm R, Erilä T, Palomäki H, Murros K, Rissanen A, Sarna S. A randomized, double-blind, placebo-controlled trial of nimodipine in acute ischemic hemispheric stroke. Stroke 1994 Jul;25(7):1348-1353.
  38. Schrader J, Lüders S, Kulschewski A, Berger J, Zidek W, Treib J, Einhaupl K, Diener HC, Dominiak P; Acute Candesartan Cilexetil Therapy in Stroke Survivors Study Group. The ACCESS study: evaluation of Acute Candesartan Cilexetil Therapy in Stroke Survivors. Stroke 2003 Jul;34(7):1699-1703.
  39. Sandset EC, Bath PM, Boysen G, Jatuzis D, Kõrv J, Lüders S, Murray GD, Richter PS, Roine RO, Terént A, et al. The angiotensin-receptor blocker candesartan for treatment of acute stroke (SCAST): a randomised, placebo-controlled, double-blind trial. Lancet 2011 Feb;377(9767):741-750.
  40. Potter JF, Robinson TG, Ford GA, Mistri A, James M, Chernova J, Jagger C. Controlling hypertension and hypotension immediately post-stroke (CHHIPS): a randomised, placebo-controlled, double-blind pilot trial. Lancet Neurol 2009 Jan;8(1):48-56.
  41. Robinson TG, Potter JF, Ford GA, Bulpitt CJ, Chernova J, Jagger C, James MA, Knight J, Markus HS, Mistri AK, et al. Effects of antihypertensive treatment after acute stroke in the Continue or Stop Post-Stroke Antihypertensives Collaborative Study (COSSACS): a prospective, randomised, open, blinded-endpoint trial. Lancet Neurol 2010 Aug;9(8):767-775.
  42. Jauch EC, Saver JL, Adams HP, Bruno A, Demaerschalk BM, Khatri P, McMullan PW, Qureshi AI, Rosenfield K, Scott PA, et al. Guidelines for the early management of patients with acute ischemic stroke. Stroke 2013 Mar;44(3):870-947.
  43. Ahmed N, Wahlgren N, Brainin M, Castillo J, Ford GA, Kaste M, Lees KR, Toni D; SITS Investigators. Relationship of blood pressure, antihypertensive therapy, and outcome in ischemic stroke treated with intravenous thrombolysis. Stroke 2009 Jul;40(7):2442-2449.
  44. Karachalios GN, Charalabopoulos A, Papalimneou V, Kiortsis D, Dimicco P, Kostoula OK, Charalabopoulos K. Withdrawal syndrome following cessation of antihypertensive drug therapy. Int J Clin Pract 2005 May;59(5):562-570.
  45. PROGRESS Collaborative Group. Randomised trial of a perindopril-based blood-pressure-lowering regimen among 6,105 individuals with previous stroke or transient ischaemic attack. Lancet 2001 Sep;358(9287):1033-1041.
  46. Schrader J, Lüders S, Kulschewski A, Hammersen F, Plate K, Berger J, Zidek W, Dominiak P, Diener HC; MOSES Study Group. Morbidity and mortality after stroke, eprosartan compared with nitrendipine for secondary prevention. Stroke 2005 Jun;36(6):1218-1226.
  47. Yusuf S, Diener HC, Sacco RL, Cotton D, Ôunpuu S, Lawton WA, Palesch Y, Martin RH, Albers GW, Bath P, et al. Telmisartan to prevent recurrent stroke and cardiovascular events. N Engl J Med 2008 Sep;359(12):1225-1237.
  48. Kernan WN, Ovbiagele B, Black HR, Bravata DM, Chimowitz MI, Ezekowitz MD, Fang MC, Fisher M, Furie KL, Heck DV, et al. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack. Stroke 2014 Jan:45(7):2160-2236.
  49. Robb AO, Mills NL, Din JN, Smith IB, Paterson F, Newby DE, Denison FC. Influence of the menstrual cycle, pregnancy, and preeclampsia on arterial stiffness. Hypertension 2009 Jun;53(6):952-958.
  50. Avni B, Frenkel G, Shahar L, Golik A, Sherman D, Dishy V. Aortic stiffness in normal and hypertensive pregnancy. Blood Press 2010 Feb;19(1):11-15.
  51. Khalil A, Akolekar R, Syngelaki A, Elkhouli M, Nicolaides KH. Maternal hemodynamics at 11–13 weeks’ gestation and risk of pre-eclampsia. Ultrasound Obstet Gynecol 2012 Jul;40(1):28-34.
  52. Medical Research Council trial of treatment of hypertension in older adults: principal results. MRC Working Party. BMJ 1992 Feb;304(6824):405-412.
  53. Dahlof B, Devereux RB, Kjeldsen SE, Julius S, Beevers G, Faire U, Fyhrquist F, Ibsen H, Kristiansson K, Lederballe-Pedersen O, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol. Lancet 2002 Mar;359(9311):995-1003.
  54. Dahlof B, Sever PS, Poulter NR, Wedel H, Beevers DG, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, et al. Prevention of cardiovascular events with an antihypertensive regimen of amlodipine adding perindopril as required versus atenolol adding bendroflumethiazide as required, in the Anglo-Scandinavian Cardiac Outcomes Trials-Blood Pressure Lowering Arm (ASCOT-BPLA): a multicentre randomised controlled trial. Lancet 2005 Sep;366(9489):895-906.
PDF Share
PDF Share

© Jaypee Brothers Medical Publishers (P) LTD.